文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉联合普托马尼治疗耐药肺结核时不同剂量利奈唑胺的有效性与安全性:开放标签随机临床试验

Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在印度开展的多中心平行组随机临床试验纳入403例准广泛耐药或治疗不耐受/无反应耐多药肺结核成人,比较贝达喹啉+普托马尼联合利奈唑胺600 mg用26周、600 mg用9周后300 mg用17周、600 mg用13周后300 mg用13周三种方案。治疗结束时三组治愈率分别为93%、94%、93%,骨髓抑制无显著差异,周围神经病变三组分别30、17、19例(P=0.02)。结论认为结构化减量至300 mg/d与标准600 mg剂量疗效相当且周围神经病变更少。

要点

  • 准广泛耐药或耐多药肺结核成人中,利奈唑胺减量至300 mg/d与600 mg/d疗效相当。
  • 三组治愈率分别为93%、94%、93%,骨髓抑制无显著差异。
  • 周围神经病变三组分别30、17、19例(P=0.02),减量组更少。

核心结论

  • 在准广泛耐药或治疗不耐受/无反应耐多药肺结核成人中,贝达喹啉和普托马尼联合利奈唑胺结构化减量至300 mg/d与标准600 mg剂量疗效相当,且周围神经病变病例更少。

研究设计与样本

  • 多中心、平行组、随机临床试验,在印度开展,纳入准广泛耐药或治疗不耐受/无反应耐多药肺结核成人。
  • 患者随机接受26周贝达喹啉、普托马尼和每日利奈唑胺:第1组600 mg用26周;第2组600 mg用9周后300 mg用17周;第3组600 mg用13周后300 mg用13周。
  • 共纳入403例患者,255例(63%)<30岁,273例(68%)有既往结核病史,238例(59%)营养不良。

主要发现

  • 治疗结束时,排除基线培养阴性者后,第1、2、3组治愈分别为120例(93%)、117例(94%)、115例(93%)。
  • 骨髓抑制在第1组和第2组各85例、第3组77例,无显著差异。
  • 周围神经病变共66例(第1、2、3组分别30、17、19例),发生于10-26周(P=0.02)。
  • 因毒性减少利奈唑胺剂量者第1、2、3组分别13、2、4例。

临床怎么用

  • 作者认为,在准广泛耐药或治疗不耐受/无反应耐多药肺结核成人中,贝达喹啉和普托马尼联合利奈唑胺结构化减量至300 mg/d与标准600 mg剂量疗效相当且周围神经病变更少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid's toxicity profile, prudence suggests reconsidering its dose and duration. We determined the effectiveness and safety of structured dose reduction of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant (pre-XDR) or treatment-intolerant/nonresponsive multidrug-resistant (MDRTI/NR) pulmonary tuberculosis. METHOD: Adults with pre-XDR or MDRTI/NR pulmonary tuberculosis were enrolled in a multicenter, parallel-group, randomized clinical trial in India. Patients were randomized to 26 weeks of bedaquiline, pretomanid, and daily linezolid, at 600 mg for 26 weeks (arm 1); 600 mg for 9 weeks followed by 300 mg for 17 weeks (arm 2); or 600 mg for 13 weeks followed by 300 mg for 13 weeks (arm 3). Study end points included sustained cure, bacteriological failure, toxicity, and death. RESULTS: Of 403 patients enrolled, 255 (63%) were <30 years old, 273 (68%) had prior tuberculosis episodes, and 238 (59%) were malnourished. At the end of treatment, after excluding those with negative baseline cultures, cure was seen in 120 (93%), 117 (94%), and 115 (93%) in arms 1, 2, and 3 respectively. Myelosuppression seen in 85 patients each in arms 1 and 2 and 77 patients in arm 3, not significantly different. Peripheral neuropathy was noticed in 66 patients (30, 17, and 19 in arms 1, 2, and 3) at 10-26 weeks (P = .02). The linezolid dose was reduced because of toxicity in 13, 2, and 4 patients in arms 1, 2, and 3, respectively. CONCLUSIONS: In adults with pre-XDR or MDRTI/NR pulmonary tuberculosis, structured linezolid dose reduction to 300 mg/d is as effective as the standard 600-mg dose but with fewer cases of peripheral neuropathy when given with bedaquiline and pretomanid. CLINICAL TRIALS REGISTRATION: Clinical Trial Registry of India (CTRI/2021/03/032189).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Padmapriyadarsini C, Oswal VS, Jain CD, et al. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin Infect Dis. 2024. PMID: 39194339. doi:10.1093/cid/ciae388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。